Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

NCT03764618 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.

NCT NCT03764618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03764618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Lead sponsor
Rigel Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
April 24, 2019
Completion date
April 11, 2022
Enrollment
90 (actual)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

warm antibody autoimmune hemolytic anemia